News for Innate Pharma S.A. (IPH.PA)

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”) today announced that members of its executive team

Shares of Logility Supply Chain Solutions, Inc. LGTY rose sharply in today's pre-market trading after Aptean announced an agreement to acquire Logility in a $14...

Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Regulatory News: Pursuant to the article L. 233-8 II of the French ”œCode de Commerce” and the article 223-16 of the French stock-market authorities (Auto

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”) today announced its updated strategy for company gr

Shares of Edgewise Therapeutics, Inc. EWTX rose sharply in today's pre-market trading after the company reported topline results from Phase 2 CANYON trial of Se...

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”) today released its 2025 financial calendar: Marc

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET ® IPH6501

With U.S. stock futures trading slightly lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expect...

Innate Pharma SA:  Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024

“Natural Killer (NK) Cell Therapeutics Market” from 2024-2034 with covered segments (Natural Killer (NK) Cell Therapeutics Market, By Type (NK Cell...

California-based semiconductor business Peraso Inc. (PRSO) is down over 41 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Infobird Co., Ltd (IFBD) is up over 80% in Tuesday's pre-market trading. The following are some of the other stocks making big moves..

The following are some of the stocks making big moves in Monday's pre-market trading (as of 08.15 A.M. ET)..

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

Read Windtree Therapeutics (NASDAQ:WINT) & Innate Pharma (NASDAQ:IPHA) Head-To-Head Comparison at ETF Daily News